Pipeline Programs↗
Active Trials↗
Companies Involved↗
Hemorrhage is a highly competitive landscape with 105 programs across 43 companies. 12 programs are in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
93%
Small molecule
92 of 99 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 99 classified programs, each share of the total. Modality classified for 98% of 105 pipeline programs.
Analysis
413
clinical trials
Clinical Trials
413 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)